StockData

NewAmsterdam Pharma vs Tenax Therapeutics

NAMS and TENX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricNAMSTENX
Size and price
Market cap–$53.1M
Share price$19.39$1.42
Change, 1 year−49.4%−80.0%
Change, 5 years98.1%−99.9%
Beta (5Y)1.570.72
Employees10014
StockData Score
Total score66
Valuation score01 (better)
Growth score00
Performance score1 (better)0
Health score55
Dividend score00
Valuation
P/B–0.5×
Growth
Revenue growth (TTM)−88.9%–
Profitability
Operating margin−3432%–
Net margin−3644%–
FCF margin−2018%–
Return on equity−36.8% (better)−59.8%
Return on invested capital−1046%–
Financial health
Debt / equity0.000.00
Current ratio9.0315.07 (better)
Altman Z-score–−1.41
Piotroski F-score3 (better)2
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions–81.1%
Held by insiders22.0%4.8%
Insider net buying, 12 months−$63.0M$6.5M (better)
Short interest, % of float–16.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.